Posted in Investment Idea, Small Cap, US Investment Thesis: LONG TransAct Technologies (TACT LN Equity) Maxim Bogomaz posted on January 1, 2022January 1, 2022 No Comment TACT is a hidden growing company inside a stable company situation rebounding from the COVID impact. The casino segment provides printers for slot machines and is a cash machine in a duopoly with high switching costs. The product is critical to the slot machine’s operations while being a small fraction of the overall cost. This business in combination with some change from other small segments is worth ~80% of the current market cap (excluding cash) in a normalised environment. This means you can buy the back-office restaurant and c-store software and labelling business with 60%+ GM for 0.5x FY23 ARR. Most of this ARR is already in the backlog. Moreover, the company has one of the best products on the market, operates in the industry with secular tailwinds and recently signed a partnership with Apple, which will allow it to penetrate mostly greenfield opportunities. Read More
Posted in Idea Update, Small Cap, US Update for IDN: Good Buying Opportunity Maxim Bogomaz posted on May 17, 2021May 17, 2021 No Comment Since I wrote about IDN, the stock went down 18% and 2 quarters passed, so I think it is time to make an update. Read More
Posted in Investment Idea, Small Cap, US Investment Thesis: LONG Intellicheck (IDN LN Equity) Maxim Bogomaz posted on December 23, 2020June 10, 2021 No Comment Intellicheck is an offline and online identity authentication software company. It is the only company that can authenticate the documents with close to 99% accuracy rates at a price substantially cheaper than other identity verification competitors. This advantage is protected by its long-standing relationships with government entities, structurally cheaper product and its knowledge of information encoded in barcodes on driving licenses. The company has signed 5 out of 10 big banks and can grow its revenue 11 times just by continuing penetrating these banks’ retail customers with only one of the use cases. The opportunity is multiples of that, considering upselling of new use cases, signing new banks and expanding into new verticals. I expect the company to grow revenue at around 40% CAGR over the next 5 years. Intellicheck has very a scalable product with gross margins of ~90%. The company has strong operating leverage and is at an inflexion point to become profitable. Intellicheck can get to 52% EBITDA margin by 2025. A new CEO has skin in the game and has shown excellent execution over the last couple of years. At 20x EV/EBITDA or 10x EV/Sales exit, this is at least a 25% IRR opportunity over the next 5 years. Read More
